Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial by Fernandes, Ana Luisa Godoy et al.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
ABSTRACT
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
INTRODUCTION
Asthma is one of the most frequent
respiratory diseases, in patients of any age,
gender and/or race. Prevalence is around 10%
to 15% in children all over the world.1-3
The asthma treatment paradigm has
changed over the past 10 years, with
preventive treatment of underlying airway
inflammation using inhaled corticosteroids
replacing the previous emphasis on symptom
relief with short acting beta agonists.
Some meta-analyses comparing the
newer inhaled corticosteroids budesonide
and fluticasone propionate to beclome-
thasone  dipropionate have shown evidence
of limitations in improvement in pulmonary
function and other variables. Fluticasone
propionate at half dose was more effective
than budesonide and as effective as beclome-
thasone  dipropionate in improving peak
expiratory flow rate.4 However, the limited
availability of data with similar criteria for
symptom monitoring has made it difficult
to compare studies using fluticasone pro-
pionate, budesonide and beclomethasone
dipropionate.5
Randomized placebo-controlled, double-
blind, clinical trials with adequate metho-
dology may be a better way to demonstrate
results than studies with a large number of
patients but less uniform data collection.
Budesonide is an inhaled corticosteroid
with high topical potency and low systemic
activity. Budesonide via a breath-activated,
multi-dose, dry-powder inhaler is reco-
mmended in the treatment of chronic
asthma.6
The clinical efficacy of an inhaled drug
is greatly influenced by the device used to
deliver the drug into the lungs. Factors such
as pulmonary deposition and compliance
with treatment may influence the results of
a comparative study on the efficacy of two
drugs. Pulmonary deposition of budesonide
in healthy volunteers has been shown to be
32% of the nominal dose when using a
breath-activated, multi-dose, dry-powder
inhaler, and between 15 - 18% when using
pressurized metered dose inhalers.7
Broad clinical experience has de-
monstrated the efficacy and tolerability of
budesonide in the treatment of asthma in
adults and children.8-11
There is evidence that inhaled corti-
costeroid in the treatment of moderate
asthma may reduce the need for oral
corticosteroid treatment. However, some
questions remain regarding the real benefits
of this therapy for patients with mild
asthma.12
Some clinicians are skeptical about
transferring meta-analysis results to clinical
practice. Thus, the use of budesonide for
mild-to-moderate stable asthmatics must be
rigorously evaluated in randomized con-
trolled clinical trials.
The objective of this study was to assess
the efficacy and tolerability of budesonide
400 µg (bid) in asthmatic patients for 8
weeks, compared with a placebo, both
administered via a breath-activated, multi-
dose, dry-powder inhaler. The primary
efficacy variables were: change from baseline
in forced expiratory volume in the first
second (FEV1) and peak expiratory flow.
• Ana Luisa Godoy Fernandes
• Sonia Maria Faresin
• Maria Marta Amorim
• Carlos Cézar Fritscher
• Carlos Alberto de Castro Pereira
• José Roberto Jardim
Inhaled budesonide for
adults with mild-to-moderate
asthma: a randomized
placebo-controlled,
double-blind clinical trial
Hospital São Paulo, Universidade Federal de São Paulo/Escola Paulista de
Medicina, São Paulo; Respiratory Division, Hospital do Servidor Público
Estadual, São Paulo; Pneumology Division, Pontifícia Universidade
Católica, Rio Grande do Sul, Brazil
CONTEXT: Budesonide is an inhaled corticosteroid
with high topical potency and low systemic
activity recommended in the treatment of chronic
asthma.
OBJECTIVE: This study was conducted to determine
the efficacy and safety of inhaled budesonide
via a breath-activated, multi-dose, dry-powder
inhaler.
TYPE OF STUDY: Multicenter randomized parallel-
group, placebo-controlled, double-blind, clinical
trial.
SETTING: Multicenter study in the university units.
PARTICIPANTS: Adult patients with mild-to-moderate
asthma that was not controlled using
bronchodilator therapy alone.
PROCEDURES: Comparison of budesonide 400 µg
administered twice daily via a breath-activated,
multi-dose, dry-powder inhaler with placebo, in
43 adult patients (aged 15 to 78 years) with
mild-to-moderate asthma (FEV1 71% of predicted
normal) that was not controlled using
bronchodilator therapy alone.
MAIN MEASUREMENTS: Efficacy was assessed by
pulmonary function tests and asthma symptom
control (as perceived by the patients) and the
use of rescue medication.
RESULTS: Budesonide 400 µg (bid) was significantly
more effective than placebo in improving
morning peak expiratory flow (mean difference:
67.9 l/min; P < 0.005) and FEV1 (mean
difference: 0.60 l; P < 0.005) over the 8-week
treatment period. Onset of action, assessed by
morning peak expiratory flow, occurred within
the first two weeks of treatment.
CONCLUSIONS: Budesonide via a breath-activated,
multi-dose, dry-powder inhaler results in a rapid
onset of asthma control, which is maintained over
time and is well tolerated in adults with mild-to-
moderate asthma.
KEY WORDS: Asthma. Inhaled corticosteroid.
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METHODS
The procedures that follow were in
accordance with the ethical standards of the
committee responsible for human experi-
mentation and with the Helsinki Declaration
of 1975, as revised in 1983. All three
Institutions had approval from Independent
Ethics Committees for conducting the study.
General design of the study
This was a randomized, double-blind,
placebo-controlled, multicenter study,
performed at two Universitary centers and
one reference center  for asthmatic patients
(Hospital São Paulo, Universidade Federal de
São Paulo/Escola Paulista de Medicina, São
Paulo, n = 22; Respiratory Division, Hospital
do Servidor Público Estadual, São Paulo, n
= 12; Pneumology Division, Pontifícia
Universidade Católica, Rio Grande do Sul,
n = 9) with parallel groups, from June 1997
to January 1998, with eight weeks of follow-
up. All the studied drug was stored in
multidose dry powder inhalers with same
appearance and 200 doses/device. The drug
was prepared  and labeled by the pharma-
ceutical company. 60 devices were numbered,
and divided between budesonide or placebo.
The randomization was performed before the
delivery to the centers. The blind was kept
on during preparation and the trial, and the
seal was opened before the analyses.
Participants
Inclusion criteria: Patients with mild-to-
moderate asthma, according to the
international guidelines for diagnosis and
management of asthma, were included. They
had pre-bronchodilator FEV1 of between
40% and 90% of the predicted normal value
at visit one (reference values from the Brazilian
Council of Spirometry15) and an increase of
12% and 200 ml in FEV1 after 500 µg of
terbutaline sulfate (Bricanyl Turbohaler).
After receiving instructions, the patients had
to be able to use the Turbohaler according to
the product utilization techniques, as well as
fill in the diary correctly. During the run-in
period the patient were to use the rescue
medication at least 6 times in 7 days (but never
exceeding 3 inhalations/day), or for night
awakenings due to asthma at least 2 times
during the 14 days.
Exclusion criteria: Pregnant or breast-
feeding women, and individuals with other
chronic pulmonary diseases, clinically
relevant respiratory infections, or
participation in other drug investigation
studies during the 4 weeks prior to visit 1,
were excluded.
Procedures
Patients stopped their usual glicocorti-
costeroid inhaler therapy 2 weeks prior to
inclusion in the run-in period and they were
asked to complete a diary card every day, in
the morning and evening, with their asthma
symptoms, need for rescue medication, and
peak expiratory flow. The use of beta-2
agonist was allowed for symptom relief, and
was to be recorded in the diary cards.
After the run-in period, patients who had
asthma symptoms according to GINA10 were
randomized into one of the two treatment
groups, taking either two daily doses of
budesonide 400 µg (Inhaled corticosteroid:
Pulmicort Turbohaler 200 µg/dose, Astra
Draco AB, Sweden) or placebo (Placebo
Turbohaler, Astra Draco AB, Sweden).
Patients were also requested to rinse their
mouths after the use of the inhaled
medication.
The patients were instructed to contact
the investigator every time they had to double
the use of rescue medication, if the symptom
score increased and/or if they had a reduction
of 30% or more in their peak flow
measurement compared with baseline. Every
time this happened it was considered that the
patient was having an asthma exacerbation,
and a course of prednisolone 40 mg a day
for 5 days was prescribed. Three consecutive
courses of oral corticosteroids or hospita-
lization due to asthma symptoms were consi-
dered to be treatment failure, and such
patients were withdrawn from the study.
Patients were asked to come to the center
every 14 days and were requested to avoid
the use of rescue medication during the 6
hours prior to spirometry and clinical
evaluations.
Main outcome measurements
The primary efficacy variables were:
change from baseline in forced expiratory
volume in the first second (FEV1) and peak
expiratory flow. Secondary variables were:
presence of asthma symptoms, use of rescue
medication and number of exacerbations
during the study period. Peak expiratory flow,
symptoms, and bronchodilator use over the
14 days before the visit were obtained from
diary cards.
FEV1 and peak expiratory flow. During
each visit, besides clinical evaluation,
spirometry was performed according to the
Brazilian Consensus of Spirometry, and the
following parameters were measured: FEV1
(forced expiratory volume in one second) and
FVC (forced vital capacity), before and after
the use of bronchodilator (terbutaline sulfate
0.5 mg).13,14 During all visits, patients were
asked about any adverse event, whether or
not it had any relationship to the study
treatment.
Investigator’s opinion. At the end of the
study, the investigator’s opinion about
efficacy and tolerability of the drug was
obtained in comparison with the run-in
period: Excellent - complete control of
symptoms; Good - few symptoms; Medium
- reduction but persistence of symptoms;
Insufficient - same symptoms.
Asthma symptoms. Every morning and
evening, the patient performed an evaluation
of his/her asthma symptoms over the
preceding day or night period. This
evaluation included an overall assessment of
the following symptoms: shortness of breath,
chest discomfort, wheezing and cough. The
following scale was used to record these
combined symptoms: Point scale for
nocturnal symptoms: 0 = no night awakening
due to asthma; 1 = one night awakening due
to asthma; 2 = more than one night
awakening due to asthma; 3 = could not sleep
due to asthma; Point scale for daytime
symptoms: 0 = no symptoms at all,
unrestricted activity; 1 = symptoms caused
little or no discomfort, unrestricted activity;
2 = symptoms caused some discomfort, at
times limiting strenuous activity; 3 =
symptoms caused moderate discomfort,
limited routine activity.
The number of inhalations taken during
the day and night were recorded in the
patient diary card. Patients were also
requested to record the peak expiratory flow
in l/min daily, in the morning and evening,
before taking the study medication and,
preferably, at least 6 hours after rescue
medication use. On each occasion they were
asked to measure peak expiratory flow three
times, while standing up, and record the
highest value in the diary.
Statistical methods
Calculation of the sample size. It was
estimated that up to the 60th patient should
be included (there were 60 medications
prepared for randomization).
Statistical analysis. Student’s t test was
utilized for comparisons of the numerical
variables and the chi-squared test for
comparisons of category variables between
budesonide and placebo. Friedman’s test was
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applied to observe variables in each individual
and the Mann-Whitney test for comparison
of variables in individuals between groups
(budesonide or placebo) at each visit. For
statistical calculations of the score values
obtained from the diaries, the reference value
was the average of the values in the run-in
period for each patient. For all tests, a level
of 0.05 or 5% was established for rejection
of the null hypothesis.
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RESULTS
Protocol deviations
Of the 43 adult patients selected for the
run-in period, 23 were randomized to the
budesonide group and 20 to the placebo
group. Forty-one patients completed the 8
week randomized period of the study. Two
patients, one from each group, were excluded
from the study because the occurrence of
severe acute of asthma exacerbation
Baseline characteristics
No significant differences were observed
among subject characteristics at the time of
inclusion in the protocol (Table 1). Table 2
shows the variables studied and the changes
from baseline that were statistically signi-
ficant have been marked with an asterisk.
Main outcomes measurements
The pre-bronchodilator FEV1 values
showed a significant increase from 2.3 l to
2.8 l in the budesonide group (P < 0.001)
after the 2nd week of treatment, in
comparison with the placebo group (P <
0.05) (Figure 2).
Morning peak expiratory flow values
were significantly higher in the budesonide
group (P < 0.001) after 2 weeks of treatment.
The symptom score (diurnal and nocturnal)
showed significant reduction in the
budesonide group, as well as the use of beta-
2 agonist for symptom relief, after 2 weeks
of treatment (Table 2).
Three patients in the budesonide group
and 5 in the placebo group presented asthma
exacerbation and took a course of prednisone
40 mg daily for 5 days during the trial.
Although there was a higher number of
exacerbations in the placebo group, this
difference did not reach statistically
significant values (P = 0.27). There was no
difference in the occurrence of adverse events
between the two groups.
Table 3 presents the efficacy of the treatment
according to the investigator´s opinion.
Table 1. Subjects characteristics before randomization (visit 0)
Groups
Budesonide 800 µg Placebo
Chracteristics n = 23 n = 20 P
Age, years (SD). 31.7 (15.5) 36.2 (13.2) n.s.
Male (%). 8 (34.8) 4 (20) n.s.
Female (%). 15 (65) 16 (8) n.s.
FEV1 pre-bronchodilator liters (%). 2.3 (71.5) 2.2 (77.5) n.s.
FEV1 post-bronchodilator liters (%). 2.7 (83.3) 2.6 (77.50) n.s.
·Mann-Whitney test: not significant (n.s.).
week 2 week 0 week 2 week 4 week 8
Budesonide 2.3(0.7) 2.3(0.8) 2.7(0.6) 2.8 (0.5) 2.7(0.7)
Placebo  2.1(0.8) 2.2(0.7) 2.0(0.9) 2.1 (0.9) 2.1(0.7)
Figure 2. Changes in FEV1 over 8 weeks, using budesonide (solid line) and placebo (dotted line).
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Figure 1. Study profile.
Analysed Analysed
Excluded = 1 Excluded = 1
Drop-outs = 0 Drop-outs = 0
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DISCUSSION
Asthma is a chronic disease with variable
clinical expression and airway inflammation
underlies all levels of asthma severity. To
achieve good clinical control, patient
monitoring through assessment of symptoms
and clinical signs is needed.
This study showed that treatment with
budesonide via Turbohaler of adults with
mild-to-moderate asthma has a rapid onset
of disease control, which is maintained for
more than eight weeks and is well tolerated.
It was the first time that second-generation
inhaled glucocorticosteroids had been tried
in our country. The study was especially
designed to test efficacy and safety of
budesonide in asthmatics
Patients had had their asthma diagnosed
at least one year prior to entering the study,
with persistent clinical symptoms and
expression of mild-to-moderate asthma
according to GINA.10 To prove its efficacy,
budesonide 800 µg/day (bid) was used and
the follow-up included the monitoring of
bronchial obstruction, asthma symptoms
and rescue medication use, as well as the
occurrence of asthma exacerbation during
the trial.
Several studies have shown the efficacy of
inhaled long-acting beta-2 agonists for mild-
to-moderate asthma, leading to a reduction
of diurnal and nocturnal symptoms and an
improvement in pulmonary function. A
double-blind study with a combination of
formoterol to budesonide in high and low
doses (FACET study) showed good clinical
control, but the number of severe
exacerbations was even lower in patients with
higher doses of budesonide. Increasing the
maintenance dose of inhaled corticosteroid
might be a more appropriate initial treatment
for patients with unstable asthma. However,
decisions about appropriate therapy will
depend upon the patient’s medical history,
symptoms, clinical characteristics and previous
treatment choices.15,16
The clinical protocol was designed such
that patients with symptomatic asthma had
the disease confirmed by the presence of
daytime and evening symptoms of mild-to-
moderate asthma during the run-in period
of two weeks. The improvement in asthma
control was linked to the budesonide
treatment twice daily. Our patients presented
a significant reduction in the symptom score
and use of rescue medication associated with
budesonide 800 µg/day (Table 2). If we
Table 2. Forced expiratory volume pre- and post-bronchodilator, morning peak flow, day
and night symptom scores, and beta agonist usage over the trial
Grupos
budesonide placebo Comparison between groups**
FEV1 pre bd
week. –2 2.3 (SD 0.7) 2.1 (SD 0.8) n.s.
week. 0 2.3 (SD 0.8) 2.2 (SD 0.7) n.s.
week. 2 2.7 (SD 0.6) 2.0 (SD 0.9) p < 0.05
week. 4 2.8 (SD 0.5) 2.1 (SD 0.9) p < 0.05
week 6 - - -
week 8 2.7 (SD 0.7) 2.1 (SD 0.7) p < 0.05
p* p < 0.001 n.s.
FEV1 post bd
week. –2 2.8 (SD 0.6) 2.7 (SD 0.7) n.s.
week. 0 2.7 (SD 0.5) 2.6 (SD 0.5) n.s.
week. 2 3.0 (SD 0.7) 2.4 (SD 0.8) p < 0.05
week. 4 3.0 (SD 0.6) 2.5 (SD 0.6) n.s.
week 6 - - -
week 8 3.0 (SD 0.7) 2.5 (SD 0.7) n.s.
p* n.s. n.s.
morning peak expiratory flow
week. 0 329.8 (SD 99.6) 301.1 (SD 71.5) n.s.
week. 2 348.2 (SD 117.1) 294.6 (SD 73.6) p < 0.05
week. 4 375.3 (SD 112.4) 313.8 (SD 64.0) p < 0.05
week 6 385.6 (SD 118.3) 317.7 (SD 75.1) p < 0.05
week 8 387.1 (SD 120.8) 319.2 (SD 67.9) p < 0.05
p* p < 0.001 n.s.
day symptoms        ( Min-Max)        ( Min-Max)
week. 0 0.9  (0.07- 2.3) 0.6 (0.07 - 1.1) n.s.
week. 2 0.5  (0.0  - 2.2) 0.8 (0.0   - 3.0) n.s.
week. 4 0.4  (0.0   -1.7) 0.7 (0.0   - 1.4) n.s.
week 6 0.5  (0.0  - 2.1) 0.6 (0.0   - 1.5) n.s.
week 8 0.3  (0.0  - 1.7) 0.5 (0.08  - 1.1) n.s.
p* p < 0.01 n.s.
night symptoms        ( Min-Max)        ( Min-Max)
week. 0 0.9 (0.1 - 2.3) 0.7 (0.07 - 1.7) n.s.
week. 2 0.5 (0.0 - 2.2) 0.7 (0.0   - 1.5) n.s.
week. 4 0.4 (0.0 - 1.6) 0.6 (0.0   - 1.4) n.s.
week 6 0.4 (0.0 - 1.6) 0.6 (0.0   - 1.5) n.s.
week 8 0.4 (0.0 – 1.7) 0.5 (0.08 -  1.1) n.s.
p* p < 0.01 n.s.
beta 2 use: day
week. 0 1.0 (SD 0.7) 0.8 (SD 0.5) n.s.
week. 2 0.7 (SD 0.7) 0.9 (SD 0.7) n.s.
week. 4 0.5 (SD 0.5) 0.8 (SD 0.6) n.s.
week 6 0.4 (SD 0.5) 0.7 (SD 0.7) n.s.
week 8 0.4 (SD 0.5) 0.6 (SD 0.5) n.s.
p* p < 0.01 n.s.
beta 2 use: night
week. 0 1.1 (SD 0.7) 1.2 (SD 0.5) n.s.
week. 2 0.9 (SD 0.7) 1.3 (SD 0.7) n.s.
week. 4 0.9 (SD 0.5) 1.1 (SD 0.6) n.s.
week 6 0.8 (SD 0.5) 1.1 (SD 0.7) n.s.
week 8 0.8 (SD 0.5) 1.0 (SD 0.5) n.s.
p* p = 0.06 n.s.
* comparison over time - Friedman test. ** comparison between groups - Mann Whitney test. bd = bronchodilator
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consider that asthma is an inflammatory
disease in which the clinical manifestations
are a consequence of inflammatory me-
diators, the use of beta-2 agonist for symptom
relief is a good parameter for evaluation of
the inflammatory activity of the disease.
According to Busse et al,17 the reduction in
asthma attacks with the regular use of
budesonide means an improvement in the
inflammatory process of the bronchial
mucosa.
The patients’ pulmonary functions and
clinical conditions did not differ before
randomization (visit 2) (Table 1). Thus, both
groups started the study under the same
conditions, which guaranteed that observed
results reflected the given therapy.
Several studies in the medical literature
have shown the efficacy of inhaled
corticosteroids in the control of moderate
asthma,18 leading to a reduction in diurnal
and nocturnal symptoms and an impro-
vement in pulmonary function, as shown by
this study.
At the time this study was performed,
the long-lasting beta-2 was not available in
Brazil, and the second generation of inhaled
corticosteroids such as budesonide had just
been launched in the market. This special
situation in comparison with other countries
gave us the opportunity to make comparisons
between the drug and placebo, even in
patients with additional asthma symptoms.
With the introduction of all kinds of second-
generation inhaled corticosteroids associated
with long-lasting beta-2 agonist, it has
become less frequent to follow patients in a
study to obtain results that reflect only the
use of inhaled corticosteroids.
Busse et al,19 in another multicenter
study (473 subjects; baseline FEV1 = 63 to
66% of predicted values), showed that the
efficacy of budesonide is not dose-dependent.
They studied patients with total daily doses
of 200, 400, 800 or 1600 µg and observed
that all doses were better than placebo and
there was no difference between 400 and 800
µg. The improvement in FEV1 and peak
expiratory flow over 12 weeks of study was
also statistically significant.
The morning and evening peak expi-
ratory flow measurements (Table 2) showed
a statistically significant increase, tending to
be maintained until the end of the study,
providing a larger bronchial caliber in
patients using budesonide. The average peak
expiratory flow improvement in the
budesonide group was 60 l/min. In the
multicenter FACET study with 852
asthmatic subjects, the group that used high
doses of budesonide without beta-2 agonist
did not experience great improvement, but
patients using a long-acting beta-2 agonist
in combination with low or high doses of
budesonide showed a 40 l/min increase in
morning peak expiratory flow. In com-
parison, we obtained this result without the
use of a bronchodilator.
However, in contrast to our study,
FACET did not have a placebo group. Even
with a small number of patients in
comparison with the large multicenter
studies, our results showed that budesonide
800 µg was significantly more effective than
placebo in improving morning peak
expiratory flow (a mean difference from
placebo of 67.9 l/min; P < 0.005).
FEV1 values improved significantly (400
ml; Table 2) in patients who used budesonide
(a mean difference from placebo of 0.60 l; P
< 0.005) over the 8-week treatment period.
This gain represents the obtaining of good
control over the symptoms and a guarantee
of minimizing the remodeling process
associated with the chronic respiratory
inflammation present in asthmatic airways.
Enright et al.20 considered the gain in
FEV1 the best parameter for the follow-up of
asthmatic patients, since it represents the
improvement in pulmonary function during
one observational period and the best
condition that a patient can attain after
maximum therapy on the evaluation day. This
has a better clinical correlation with good
asthma control than bronchial responsiveness
tests for histamine or metacholine.
The frequency of asthma exacerbations
did not differ between the two groups of
patients. There were 5 occurrences in the
placebo group and 3 in the budesonide group.
A recent review of the FACET study has
concluded that exacerbations may be
predominantly associated with a change in
symptom score and in peak expiratory flow,
but the pattern (intensity of variation) was
not affected by the dose of inhaled
corticosteroid or whether the patient was
taking formoterol.21
The side effects were comparable for the
budesonide and placebo groups, and the
tolerability was considered good for both groups.
The efficacy interpreted by the
investigator did not differ statistically
between the groups (Table 3). However, there
was a predominance of excellent scores in the
budesonide group (40%), in comparison
with the placebo group (16.7%).
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CONCLUSION
Budesonide is an effective drug for
obtaining good control of patients’ asthma,
minimizing the symptom score and reducing
the use of relief medication. There was an
improvement in pulmonary function, with
a significant increase in the values of FEV1
and peak expiratory flow.
Table 3 - Efficacy of treatment according the investigator opinion.
group           group
budesonide           placebo p
Scores n % n %
Excelent 9 40.9 3 16.7
Good 5 22.7 5 27.8 n.s.
Medium 4 18.2 4 22.2
Insuficient 4 18.2 6 33.3
Total 22 100.0 18 100.0
Qui-square test:  n.s.= not significant.
Investigator opinion compared with run-in period
Excelent: complete control of symptoms, Good: minimum symptoms, Medium: reduction but persistence of symptoms, Insufficent: same expression of symptoms.
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CONTEXTO: A budesonida é um corticóide
inalatório de alta potência tópica e baixa
atividade sistêmica recomendado no
tratamento da asma crônica.
OBJETIVO: Determinar a eficácia e tole-
rabilidade da budesonida via um inalador em
pó com atividade inspiratória e multidose,
comparada com placebo, em pacientes
adultos portadores de asma leve ou moderada
não-controlados com terapia bronco-
dilatadora.
TIPO DE ESTUDO: Estudo randomizado com
dois grupos paralelos, duplo-cego, placebo
controlado.
LOCAL: Estudo multicêntrico em centros
universitários.
PARTICIPANTES: 43 pacientes adultos (idade
entre 15 e 78 anos), portadores de asma leve
ou moderada (VEF1 71% do normal previsto)
não-controlados com terapia broncodilatadora.
PROCEDIMENTOS: Para comparar, com
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RESUMO
placebo, a eficácia e tolerabilidade de 400 µg
de budesonida, administradas duas vezes ao
dia, via turbuhaler.
VARIÁVEIS ESTUDADAS: A eficácia foi
determinada através de testes de função
pulmonar, controle dos sintomas de asma e
uso de medicação de resgate.
RESULTADOS: 400 µg de budesonida duas vezes
ao dia foram significantemente mais efetivas
que placebo em relação ao aumento do peak
expiratory flow matutino (67,9 l/min. p <
0,005) e VEF1 (0,60 l/min., p < 0,05) nas
oito semanas de tratamento.
CONCLUSÃO: O tratamento com budesonida
via um inalador em pó com atividade
inspiratória e multidose, em pacientes
portadores de asma leve e moderada, é bem
tolerado e resulta em rápido e duradouro
controle da asma.
PALAVRAS-CHAVE: Asma. Corticóide inala-
tório. Budesonida.
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